AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8214993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 3312862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen cream (Pabafil SPF 10, with absorption range from 290 to 360 nm)
Number of subjects: 65
Study 3312862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 3312862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen cream
Number of subjects: 65
Study 30923309 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 57
Study 30923309 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 57
Study 28281051 — intervention group
Group type: EXPERIMENTAL
Intervention: OSG + E (therapist-led, 10-week synchronous online intervention)
Number of subjects: 105
Study 28281051 — intervention group
Group type: COMPARATOR
Intervention: E (self-help workbook)
Number of subjects: 105
Study 24738609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR (500 mg/day)
Number of subjects: 288
Study 24738609 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol PR (300 mg/day) / Pregabalin (300 mg/day)
Number of subjects: 288
Study 23672789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2‐4 mg/day
Number of subjects: 129
Study 23672789 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10‐20mg/day
Number of subjects: 129
Study 23672789 — intervention group
Group type: COMPARATOR
Intervention: Neither statin
Number of subjects: 129
Study 21732669 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-fortified broccoli (200 g daily for 4 weeks)
Number of subjects: 76
Study 21732669 — intervention group
Group type: COMPARATOR
Intervention: Regular broccoli (200 g daily for 4 weeks)
Number of subjects: 76
Study 19185634 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (guideline dissemination via a continuing medical education session, academic detailing sessions, audit and feedback, automated blood pressure machines)
Number of subjects: 61
Study 19185634 — intervention group
Group type: COMPARATOR
Intervention: Attention control (targeted at a different guideline)
Number of subjects: 61
Study 19185634 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 61
Study 19185634 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 61
Study 16874778 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered at weeks 0, 2, 6, and every 6 weeks thereafter through week 24
Number of subjects: 0
Study 16874778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12631532 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MTL lesions
Number of subjects: 18
Study 12631532 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 18
Study 10837017 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavonoids (genistein at 12.5-100 microM)
Number of subjects: 12
Study 10837017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterolactone (100 microM)
Number of subjects: 12
Study 10837017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrogenistein (100 microM)
Number of subjects: 12
Study 10837017 — intervention group
Group type: EXPERIMENTAL
Intervention: Formononetin (100 microM)
Number of subjects: 12
Study 10837017 — intervention group
Group type: COMPARATOR
Intervention: Rye crispbread (76.5 g/day for 2 weeks)
Number of subjects: 12
Study 8780091 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard carbidopa/levodopa (Std‐L)
Number of subjects: 15
Study 8780091 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release carbidopa/levodopa (L‐CR)
Number of subjects: 15
Study 1473430 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms four times daily with meals and at bedtime)
Number of subjects: 162
Study 1473430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 6233731 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30888118 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment (375 mg/m2 q3 months for 2 years)
Number of subjects: 263
Study 30888118 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 263
Study 30888118 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment
Number of subjects: 263
Study 29154407 — intervention group
Group type: COMPARATOR
Intervention: Muscle strength group (n=15)
Number of subjects: 47
Study 29154407 — intervention group
Group type: COMPARATOR
Intervention: Perturbation-based group (n=16)
Number of subjects: 47
Study 29154407 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 47
Study 26840703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injections (ISWI)
Number of subjects: 68
Study 26840703 — intervention group
Group type: COMPARATOR
Intervention: Intracutaneous isotonic saline injections (placebo treatment)
Number of subjects: 68
Study 25367539 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflecting on experiences of unconditional regard (n = 91)
Number of subjects: 247
Study 25367539 — intervention group
Group type: COMPARATOR
Intervention: Reflecting on experiences of conditional regard (n = 80)
Number of subjects: 247
Study 25367539 — intervention group
Group type: COMPARATOR
Intervention: Reflecting on other social experiences (n = 76)
Number of subjects: 247
Study 22742888 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision restoration therapy
Number of subjects: 80
Study 22742888 — intervention group
Group type: COMPARATOR
Intervention: Saccadic training (control intervention)
Number of subjects: 80
Study 20955629 — intervention group
Group type: COMPARATOR
Intervention: Condom-only control group
Number of subjects: 801
Study 20955629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm group
Number of subjects: 801
Study 20955629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 801
Study 17658567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500mg for age > or =12 years, 200mg for age 4-11 years, 100mg for age 1-3 years)
Number of subjects: 81
Study 17658567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500mg for adults with hepatic amoebiasis)
Number of subjects: 81
Study 17658567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500mg)
Number of subjects: 81
Study 16362456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 16362456 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 53
Study 16362456 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (CaCO3)
Number of subjects: 53
Study 16362456 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (CaCO3) + 1,200 IU of cholecalciferol
Number of subjects: 53
Study 12558088 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral slow-release tramadol
Number of subjects: 156
Study 12558088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 10217370 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g aged garlic extract (AGE)
Number of subjects: 0
Study 10217370 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g DL‐alpha‐tocopherol acetate
Number of subjects: 0
Study 10217370 — intervention group
Group type: COMPARATOR
Intervention: 6 g raw garlic
Number of subjects: 0
Study 9505452 — intervention group
Group type: EXPERIMENTAL
Intervention: New antenatal care programme
Number of subjects: 265
Study 9505452 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care programme (Control)
Number of subjects: 265
Study 9505452 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 265
Study 2202248 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ppm ozone
Number of subjects: 12
Study 2202248 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 12
Study 7038316 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose verapamil (0.075 mg/kg)
Number of subjects: 28
Study 7038316 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose verapamil (0.15 mg/kg)
Number of subjects: 28
Study 7038316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7038316 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (low-dose and standard-dose)
Number of subjects: 28
Study 31630358 — intervention group
Group type: EXPERIMENTAL
Intervention: TAT-SOD (0.2 mL of 3000 U/mL TAT-SOD cream) applied topically at acupoint ST 36 once a day for 15 days
Number of subjects: 16
Study 31630358 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied topically at acupoint ST 36 once a day for 15 days
Number of subjects: 16
Study 30818837 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy (ICBT)
Number of subjects: 160
Study 30818837 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (EW)
Number of subjects: 160
Study 30818837 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 160
Study 27625122 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization training in addition to traditional rehabilitation (n=12)
Number of subjects: 25
Study 27625122 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (n=13)
Number of subjects: 25
Study 27077745 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced appointment reminders (dated appointment card plus SMS and phone call reminders, or in-person reminders)
Number of subjects: 410
Study 27077745 — intervention group
Group type: COMPARATOR
Intervention: Standard appointment reminders (dated appointment card)
Number of subjects: 410
Study 24411428 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS simulator
Number of subjects: 26
Study 24411428 — intervention group
Group type: COMPARATOR
Intervention: LapSim simulator
Number of subjects: 26
Study 22541893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD) 30 mg/m² IV followed by a 3-h infusion of trabectedin 1.1 mg/m² every 3 weeks
Number of subjects: 672
Study 22541893 — intervention group
Group type: COMPARATOR
Intervention: PLD 50 mg/m² every 4 weeks
Number of subjects: 672
Study 22541893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus PLD
Number of subjects: 672
Study 22541893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus PLD in patients with PFI of 6-12 months
Number of subjects: 672
Study 20430851 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS combined with DWI
Number of subjects: 45
Study 18018769 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 SU inactivated SARS-CoV vaccine
Number of subjects: 36
Study 18018769 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 SU inactivated SARS-CoV vaccine
Number of subjects: 36
Study 18018769 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 36
Study 16081875 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory threshold load of 15 cmH2O
Number of subjects: 14
Study 12150647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Therapy (CBT)
Number of subjects: 162
Study 12150647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT)
Number of subjects: 162
Study 12150647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBT and IPT
Number of subjects: 162
Study 9920144 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 30
Study 9920144 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 30
Study 9920144 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (gemfibrozil + lovastatin)
Number of subjects: 30
Study 9920144 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil alone
Number of subjects: 30
Study 9920144 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin alone
Number of subjects: 30
Study 7501353 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal vitamin K and phenobarbital therapy
Number of subjects: 0
Study 7501353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2253912 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine (1 g twice daily)
Number of subjects: 14
Study 2253912 — intervention group
Group type: COMPARATOR
Intervention: Pentasa (750 + 500 + 750 mg daily)
Number of subjects: 14
Study 2253912 — intervention group
Group type: COMPARATOR
Intervention: Salofalk (750 + 500 + 750 mg daily)
Number of subjects: 14
Study 2253912 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 14
Study 6986082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 11894
Study 6986082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11894
Study 30683195 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Endovascular Therapy
Number of subjects: 2100
Study 30683195 — intervention group
Group type: COMPARATOR
Intervention: Best Surgical Therapy
Number of subjects: 2100
Study 28902580 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure plus antiplatelet therapy
Number of subjects: 664
Study 28902580 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 664
Study 26212317 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated reminder messages
Number of subjects: 365
Study 26212317 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 365
Study 23895150 — intervention group
Group type: EXPERIMENTAL
Intervention: Stir-fried white pepper
Number of subjects: 174
Study 23895150 — intervention group
Group type: COMPARATOR
Intervention: Montmorillonite powder
Number of subjects: 174
Study 21309696 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 and 10 mg)
Number of subjects: 34
Study 21309696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19848610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive sulfadoxine-pyrimethamine treatment
Number of subjects: 0
Study 17447832 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole 0.125, 0.25, 0.50 or 0.75 mg once daily for 3 weeks
Number of subjects: 0
Study 17447832 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole at a median dosage of 0.35 mg/day for 6 weeks
Number of subjects: 0
Study 17447832 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole for 12 weeks
Number of subjects: 0
Study 17447832 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole after 6 months' therapy
Number of subjects: 0
Study 15077870 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone high-flux hemodialysis
Number of subjects: 29
Study 15077870 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone low-flux hemodialysis
Number of subjects: 29
Study 11487163 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 36
Study 11487163 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium oxide
Number of subjects: 36
Study 10093521 — intervention group
Group type: EXPERIMENTAL
Intervention: Double papilla flap procedure
Number of subjects: 20
Study 10093521 — intervention group
Group type: COMPARATOR
Intervention: Coronally repositioned flap procedure
Number of subjects: 20
Study 7820492 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with glutamine supplementation (20 g/day for 3 days)
Number of subjects: 17
Study 7820492 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition without glutamine supplementation
Number of subjects: 17
Study 2205135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.3 mg.kg‐1
Number of subjects: 45
Study 2205135 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.33 mg.kg‐1
Number of subjects: 45
Study 2205135 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) 0.04 ml.kg‐1
Number of subjects: 45
Study 282538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic energy therapy
Number of subjects: 0
Study 282538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31243575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clown Intervention (CI)
Number of subjects: 24
Study 31243575 — intervention group
Group type: COMPARATOR
Intervention: Other Intervention (OI)
Number of subjects: 24
Study 27762095 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-1 (0.12% CHX and 0.05% CPC)
Number of subjects: 30
Study 27762095 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-2 (0.03% CHX and 0.05% CPC)
Number of subjects: 30
Study 27762095 — intervention group
Group type: COMPARATOR
Intervention: Positive control (0.12% CHX and 0.05% CPC)
Number of subjects: 30
Study 26485404 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 3 g/day for 2 weeks
Number of subjects: 12
Study 26485404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23410999 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug fixed-dose combination (FDC) of rifampicin, isoniazid, ethambutol, and pyrazinamide
Number of subjects: 18
Study 23410999 — intervention group
Group type: COMPARATOR
Intervention: Separate formulations of rifampicin, isoniazid, ethambutol, and pyrazinamide
Number of subjects: 18
Study 21422411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 6055
Study 21422411 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy alone)
Number of subjects: 6055
Study 21422411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with full-dose anticoagulation
Number of subjects: 6055
Study 19022863 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoses wear and stretching (O group)
Number of subjects: 36
Study 19022863 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoses wear, stretching, and concentric progressive resistive exercise (OC group)
Number of subjects: 36
Study 19022863 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoses wear, stretching, and eccentric progressive resistive exercise (OE group)
Number of subjects: 36
Study 19022863 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 36
Study 17302711 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) stimulation
Number of subjects: 56
Study 17302711 — intervention group
Group type: COMPARATOR
Intervention: Single right ventricular (RV) pacing
Number of subjects: 56
Study 14764774 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg/d)
Number of subjects: 100
Study 14764774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11211134 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuses of Asian mothers
Number of subjects: 170
Study 11211134 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuses of black mothers
Number of subjects: 170
Study 11211134 — intervention group
Group type: COMPARATOR
Intervention: Fetuses of white mothers
Number of subjects: 170
Study 11211134 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Asian versus white mothers
Number of subjects: 170
Study 11211134 — intervention group
Group type: COMPARATOR
Intervention: Comparison of black versus white mothers
Number of subjects: 170
Study 11263303 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dry powder (BDP, 600 micrograms/day)
Number of subjects: 59
Study 11263303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 7946871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (10 mg bolus followed by 30 mg/24 h infusion)
Number of subjects: 40
Study 7946871 — intervention group
Group type: COMPARATOR
Intervention: Control (10% Intralipid)
Number of subjects: 40
Study 7946871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 2519671 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bednets (500 mg/m2)
Number of subjects: 0
Study 2519671 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated bednets (milk)
Number of subjects: 0
Study 31112621 — intervention group
Group type: EXPERIMENTAL
Intervention: I-neb (75 mg tobramycin inhalation solution)
Number of subjects: 22
Study 31112621 — intervention group
Group type: COMPARATOR
Intervention: PARI-LC Plus (300 mg tobramycin inhalation solution)
Number of subjects: 22
Study 31112621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nebulizers (I-neb and PARI-LC Plus)
Number of subjects: 22
Study 31112621 — intervention group
Group type: EXPERIMENTAL
Intervention: I-neb
Number of subjects: 22
Study 31112621 — intervention group
Group type: COMPARATOR
Intervention: PARI-LC Plus
Number of subjects: 22
Study 27892641 — intervention group
Group type: EXPERIMENTAL
Intervention: Text + Picture stimuli
Number of subjects: 0
Study 27892641 — intervention group
Group type: COMPARATOR
Intervention: Text-only stimuli
Number of subjects: 0
Study 25248303 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective expectation manipulation
Number of subjects: 148
Study 25248303 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective expectation manipulation with elaboration
Number of subjects: 148
Study 25248303 — intervention group
Group type: COMPARATOR
Intervention: No-expectation participants
Number of subjects: 148
Study 25248303 — intervention group
Group type: COMPARATOR
Intervention: No-elaboration participants
Number of subjects: 148
Study 23597479 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care assessment using high-sensitivity cardiac troponin assays
Number of subjects: 850
Study 23597479 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous measurement of H-FABP and cTnT or cTnI
Number of subjects: 850
Study 23597479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin measured on admission
Number of subjects: 850
Study 23597479 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hour troponin measurement
Number of subjects: 850
Study 23597479 — intervention group
Group type: COMPARATOR
Intervention: Admission myoglobin
Number of subjects: 850
Study 23597479 — intervention group
Group type: COMPARATOR
Intervention: CK-MB measurement on admission
Number of subjects: 850